Clinical Trials Logo

Clinical Trial Summary

The aim of the study is to compare efficacy and tolerability of aprepitant versus dexamethasone in the prevention of delayed emesis induced by moderately emetogenic chemotherapy (cyclophosphamide plus anthracyclines) in breast cancer patients.


Clinical Trial Description

This is a phase III, double-blind, randomized trial, to evaluated the efficacy and safety of aprepitant for the prevention of delayed emesis in patients with breast cancer submitted for the first time to chemotherapy with cyclophosphamide plus anthracyclines.

The study will be carried out during the first cycle of chemotherapy.

For the prevention of acute emesis, all patients will receive, before chemotherapy:

- dexamethasone 8 mg iv in 15 minutes, 30 minutes before chemotherapy;

- palonosetron 0.25 mg iv bolus, 30 minutes before chemotherapy

- aprepitant 125 mg orally, 60 minutes before chemotherapy

After 24 hours from chemotherapy administration, patients will be randomized to receive:

A) dexamethasone 4 mg orally: 24 hours after chemotherapy and at 8 pm on day 2, then at 8 am and 8 pm on day 3.

B) Aprepitant 80 mg orally: 24 hours after chemotherapy on day 2 and then at 8 am on day 3.

The patients will receive prochlorperazine suppositories as rescue medication, for important nausea and vomiting (> 2 episodes) during days 1-5 after chemotherapy.

The patients will receive a diary, which includes a Visual Analogue Scale (VAS) for nausea and vomiting evaluation. All patients will fill out the diary in which, for 6 consecutive days (days 1-6), patients will report for each day the number of vomiting episodes, the intensity and duration of nausea, any antiemetic rescue medication and any adverse event and its treatment.

In addition, on day 1 before chemotherapy and then on day 6, patients will fill out the FLIE (Functional Living Index-Emesis), a questionnaire concerning the impact of nausea and vomiting on their quality of life.

Primary end point is the percentage of complete responses (no vomiting and no rescue treatment) on days 2-5 after chemotherapy administration ;


Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT00869973
Study type Interventional
Source S. Maria Hospital, Terni
Contact
Status Terminated
Phase Phase 3
Start date September 2009
Completion date July 2012

See also
  Status Clinical Trial Phase
Active, not recruiting NCT01913990 - Prevention of Chemotherapy Induced Nausea and Vomiting in Breast Cancer Patients. Phase 4
Terminated NCT00869310 - Aprepitant in the Prevention of Cisplatin-induced Delayed Emesis Phase 3
Completed NCT04719286 - MinSafeStart - Decision Aid Tool for Better Treatment of Nausea and Vomiting During Pregnancy N/A
Completed NCT01046240 - Pharmacokinetic Evaluation of Subcutaneous Versus Intravenous Palonosetron in Cancer Treated With Chemotherapy Phase 1/Phase 2
Recruiting NCT03478605 - Trial to Evaluate Efficacy of Olanzapine With Short-acting 5HT3 Inhibitors in Chemotherapy-induced Nausea & Vomiting (CINV) Prophylaxis Phase 2
Recruiting NCT04564144 - Evaluation of Meclizine Orodispersible Tablet Pharmacokinetic in Human Volunteers Phase 1/Phase 2
Terminated NCT01148264 - Comparison of Olanzapine and Metoclopramide For Treatment Of bReakThrough Emesis Phase 2
Completed NCT01509417 - Different Feeding Methods After Pyloromyotomy N/A
Completed NCT00152867 - Dexamethasone Study: Impact on Quality of Life of Continuing Dexamethasone Following Emetogenic Chemotherapy Phase 3
Completed NCT04182750 - Promoting Safe Medication Use in Pregnancy in the Era of Real-World Data - The SafeStart Study N/A
Completed NCT02980289 - DAnish Nausea Study In Advanced Cancer-Epidemiology: A Danish Multicenter Trial to Investigate the Prevalence and Treatment of Nausea and/or Vomiting in Patients With Advanced Cancer.
Completed NCT02602080 - Post- Surgery Recovery: Nerve Blocks w/ Sedation vs. Nerve Block w/ Either Sedation/Gen. Anesthesia
Completed NCT04585841 - The Effect of Cannabidiol on Lean Body Mass in Patients Receiving Chemotherapy Phase 1
Completed NCT01414478 - High Protein Intake to Decrease Emesis and Promote Patient Satisfaction in Labor N/A
Not yet recruiting NCT02407600 - Study Assessing Fosaprepitant in Advanced NSCLC Patients Treated With Carboplatin Based Chemotherapy Phase 2